The Archive

For decades, drug development has operated on a seductive but ultimately insufficient premise. A new paradigm is emerging at the convergence of W and E.

The concept of "network target" — acting on multiple biological nodes — is the key to understanding why botanical formulas outperform single compounds for complex disease.

How a four-herb TCM formula became one of the most rigorously studied botanical drugs in oncology — and what it teaches us about the WE Medicine approach.

The randomized controlled trial was designed for single molecules with defined mechanisms. What happens when the drug is a polychemical system acting on a network?

IC50 measures how well a drug hits one target. But what if therapeutic efficacy emerges from hitting many targets weakly? The math of polypharmacology.

Chemical fingerprinting tells you what's in a formula. Mechanism-based QC tells you whether it works. The case for a new standard in botanical drug development.

As TCM use grows alongside conventional medicine, understanding pharmacokinetic and pharmacodynamic interactions isn't optional — it's a patient safety imperative.

The Silk Road moved herbs as well as silk. TCM absorbed centuries of cross-cultural botanical knowledge. The convergence of W and E didn't start with Cheng — it started millennia ago.

Complex, heterogeneous, multisystem diseases don't respond to single-target drugs the way acute conditions do. This is precisely where WE Medicine has the most to offer.